Summary We describe the application of a simple, rapid, semi-automated assay to the sensitivity testing of cytotoxic drugs in 23 patients with acute myeloid leukaemia (AML). The survival of blast cells from the bone marrow was measured by the MTT assay after 48h continuous exposure to drugs both singly and in combination. There was a linear relationship between the number of leukaemic ceils and the optical density of the Cytotoxic drug therapy remains the prime method of treatment in acute myeloid leukaemia. One of the recognised limitations of this therapy, however, is the inability to predict tumour sensitivity in individual patients. Most attention in the field of haematological malignancies has focused on the clonogenic assay (Marie et al., 1987), dye exclusion assays (Weisenthal et al., 1986; Bird et al., 1988) and radioactive precursor incorporation (Schwarzmeier et al., 1984; Raza et al., 1987) . The advantages and disadvantages of these methods are well documented (Hill, 1983; Wiesenthal & Lippman, 1985). A simple rapid chemosensitivity test suitable for automation is what is required for routine use. The clonogenic assay is long-term, effectively measuring the chemosensitivity of dividing cells only. Evidence is emerging to suggest that non-clonogenic assays which measure cell kill in the total blast cell population may be equally valuable. The most promising of these, the dye exclusion assay, shows a good correlation with the end-point of the clonogenic assay (Weisenthal et al., 1983) . However, it is not an automated technique and is therefore timeconsuming and subject to observer error.
Cytotoxic drug therapy remains the prime method of treatment in acute myeloid leukaemia. One of the recognised limitations of this therapy, however, is the inability to predict tumour sensitivity in individual patients. Most attention in the field of haematological malignancies has focused on the clonogenic assay (Marie et al., 1987) , dye exclusion assays (Weisenthal et al., 1986; Bird et al., 1988) and radioactive precursor incorporation (Schwarzmeier et al., 1984; Raza et al., 1987) . The advantages and disadvantages of these methods are well documented (Hill, 1983; Wiesenthal & Lippman, 1985) . A simple rapid chemosensitivity test suitable for automation is what is required for routine use. The clonogenic assay is long-term, effectively measuring the chemosensitivity of dividing cells only. Evidence is emerging to suggest that non-clonogenic assays which measure cell kill in the total blast cell population may be equally valuable. The most promising of these, the dye exclusion assay, shows a good correlation with the end-point of the clonogenic assay (Weisenthal et al., 1983) . However, it is not an automated technique and is therefore timeconsuming and subject to observer error.
In 1983 Mosmann described a semi-automated colorometric assay based on the premise that the mitochondria of living cells reduce the tetrazolium salt MTT to formazan. A modified form of this is currently being successfully applied by the National Cancer Institute USA to the chemosensitivity testing of new drugs on cell lines (Alley et al., 1988) . The technique has been adapted for chemosensitivity testing of chronic (Twentyman et al., 1989) and acute (Pieters et al., 1988 ) lymphatic leukaemia cells. Results compared favourably to those using the differential staining cytotoxicity (DiSC) assay, a dye exclusion technique (Pieters et al., 1989) .
It is important to validate this assay for each cell type, and consequently we describe its application to the chemosensitivity testing of blast cells from the bone marrow of patients with acute myeloid leukaemia. These patients have a poor prognosis even in those who achieve remission. A simple in vitro method aiding initial selection of drugs both singly and in combination and permitting retesting throughout remission induction and on relapse would be a therapeutic advance.
Methods

Patients
Twenty-three patients have been tested, 18 with de novo AML and five with chronic myeloid leukaemia in blast crisis. Thirteen patients were assayed both on presentation and throughout the course of the disease, two after remission was already established, three after relapse and the remaining five patients tested initially had no follow-up as they did not survive beyond the first course of treatment.
Preparation of cells
Bone marrow (5 ml) was collected into 1 ml citrate phosphate dextrose and tested within 48 h. Peripheral blood was used in some subsequent assays if the blast cell numbers in the circulation were sufficiently high. The mononuclear cells were harvested using lymphocyte separation medium (Flow Laboratories, Rickmansworth). All samples contained >80% viable cells as checked by trypan blue dye exclusion. The morphology of the sample was assessed on a cytospin preparation using May-Grunwald-Giemsa stain.
Drug exposure
Drugs tested were doxorubicin, cytosine arabinoside, 6-thioguanine, mitoxantrone, daunorubicin, etoposide and vincristine. Stock solutions of 100 pg ml-were prepared in normal saline and stored in aliquots at -20°C. Four dilutions of each drug were made in RPMI 1640 plus 10% fetal calf serum, 25 IU ml-1 penicillin and 25 ug ml-1 streptomycin. One hundred pl of double strength drug dilution was placed in the appropriate well of a sterile flat bottomed microtitre plate and 100 p1 of a 1 x 106 cells ml -1 suspensien, also in RPMI, was added throughout giving final drug concentrations in the therapeutically relevant range (Metcalfe, 1983) . If a combination of drugs was to be tested equal quantities of each constituent were added to give an appropriate total drug concentration, 100 p1 of which were added to the wells. Two hundred pl of complete medium only was used as a blank and controls without drug were interspersed throughout the plate. Each test was set up in quadruplicate. The plate was then incubated in a humidified atmosphere for 2, 3, 4 or 7 days at 37°C in 5% CO2.
Cells were continuously exposed to the drugs throughout this period.
MTT assay
The plate was inverted followed by a rapid flick to remove the medium plus any drug (Denziot & Lang, 1986 (1989), 60, 206-210 207 balanced salt solution (HBSS) without phenol red was added to every well and the plate reincubated at 37°C in 5% CO2
for a further 4h. The formazan crystals formed were dissolved in 100 p1 acid/alcohol (0.04NHCl in isopropanol) or DMSO for comparative experiments by mixing on a microshaker (Dynatech Labs, Ltd, Billingshurst) for 10min. The plate was then read on a Dynatech microplate reader MR600 at 570nm. The number of live cells per well was calculated as a percentage of the control so measuring cell survival after drug exposure. A dose-response curve was plotted for each drug. In order to compare the results of the assay with the clinical response to the drug, patients were identified as sensitive (cell survival <30% at 1 g ml-1) or resistant (>30%) to the agents tested (Bird et al., 1988) .
shown for comparison. The formazan crystals dissolved easily in both acid/alcohol and DMSO after 10min on the microshaker. As most of the medium was removed before the addition of MTT we did not have any interference from protein precipitation when using acid/alcohol. We did, however, experience some difficulty with foaming when using DMSO (also reported by Pieters et al., 1988) and therefore chose acid/alcohol for our procedure. MTT concentration and incubation time Figure 2 shows the effect of increasing both the concentration of MTT and the incubation time. As 100 pg MTT and 4h incubation gave the greatest formazan production, this became our standard procedure.
Assessment of clinical progress
The clinical progress of the disease was assessed by the induction of complete or partial remission (Rees et al., 1986) and by the reduction in peripheral blood blast cell counts during the 48 h following cytotoxic administration. The differential white blood cell counts were performed by an independent observer.
The statistical analysis was carried out using ANOVA to compare the drug effects between patients. Linear regression with correlation coefficient was used when comparing cell numbers against formazan production and in vitro/in vivo effects.
Results
Appraisal of method
Morphology and behaviour of blasts in short-term culture
The cell suspensions from patients on presentation or in relapse contained 90 + 11% blasts. Those from patients undergoing subsequent assays during or after treatment, however, contained increasing numbers of normal cells. Control cells remained viable throughout the 48 h of the assay as measured both by the amount of formazan produced and their ability to exclude trypan blue. A small proportion of dividing cells were seen in mitosis in cytospin preparations of control samples. Similar results were obtained with fresh cells and samples stored for 48 h at 4°C. Solvents There is some controversy over the best solvent to solubilise the formazan crystals formed (Twentyman & Luscombe, 1987; Carmichael et al., 1987) . We tried both acid/alcohol and DMSO to dissolve formazan generated according to our methodology. Figure 1 shows there was no difference in their absorbence spectrum in our system. As there is some residual unconverted MTT in the wells, the spectrum of 2mg MTT ml-1 HBSS without phenol red is Cell number x 105 per well Figure 3 The relationship between the number of cells plated and the optical density of the formazan produced in three patients (O r=0.98, A r=0.97 and * r=0.98 respectively). araC, cytosine arabinoside; 6TG, 6-thioguanine.
by day 4 in two patients. These results concur with the findings of Pieters et al. (1988) . Incubation for longer than 2 days did not change the predicted sensitivity. A 48 h drug exposure was therefore chosen.
Reproducibility The repeatability of this assay in four patients is indicated in Table I . There was no significant difference (P>0.05) between the cell survival after drug exposure using the same cells on two separate occasions.
Blasts from bone marrow versus blasts from peripheral blood Figure 4 shows there is no significant difference in the behaviour of blasts from bone marrow and those from peripheral blood after exposure to 6-thioguanine, the combination of doxorubicin, cytosine arabinoside and 6-thioguanine (DAT) and mitoxantrone. The 'peripheral blood sample was taken 1 week after the bone marrow sample without the patient receiving any intermediate treatment.
Leukaemic blasts from bone marrow and peripheral blood also behave similarly in the DiSC assay (Bird et al., 1986) .
Variation in drug sensitivity The dose-response curves for patients with AML after exposure to doxorubicin, cytosine arabinoside, 6-thioguanine and mitoxantrone are shown in Figure 5 , confirming significant variation between patients. remission on this treatment. In nine cases the assay demonstrated resistance in vitro and the patients failed to gain remission. Figure 6 shows the significant correlation (P<0.0001) between the blasts killed in vitro and in vivo by the same drug or combination as above. The in vitro effect was measured as the percentage drop in cell numbers after exposure to 1 g ml-1 of single drug or 3 g ml-I total drug concentration if in combination. This was compared to the percentage fall in peripheral blood blast cells during the 48 h following cytotoxic administration. The correlation is still significant (P= 0.003), with subsequent assays carried out during remission induction despite increasing numbers of normal cells.
Clinical significance In vitro-in vivo correlation
Sequential assays One patient was tested in vitro on six separate occasions (Figure 7) . While his cells remained consistently resistant to cytosine arabinoside, the last two assays showed that doxorubicin no longer had an effect. We noted the post-treatment increase in sensitivity to doxorubicin in the fourth assay which supports the theory proposed by Selby et al. (1983) that tumour debulking may recruit a population of cells which divide actively and therefore are more sensitive to chemotherapy. There is growing evidence to support the value of non-clonogenic assays. The drug sensitivity of a sample representative of the entire tumour cell population may provide a better prediction of the tumour response and behaviour in vivo. Cytotoxic drugs are not only effective against dividing cells but alter essential cellular function in the resting phase of the cell cycle (Weisenthal & Lippman, 1985) . This damage is not measured in clonogenic assays. Most non-clonogenic methods, however, have proved relatively time-consuming. We have found the MTT assay to be simple, rapid, inexpen- Figure 6 In vitro-in vivo correlation (r=0.83, P<0.0001). Initial assay followed by first treatment (0), subsequent assays as the patients achieve remission (O r=0.72, P=0.003 The fall in peripheral blood blast cell count following drug administration was very similar to that in the in vitro assay. This may be useful as an early indication of prediction sensitivity. However, for this test to have clinical relevance the in vitro results must predict the tumour response. Our preliminary results are encouraging. The attainment of remission correlated with the results of the assay in 19 out of the 21 cases we have data for so far. In two cases we predicted that a drug would be useful when the patient did not respond. These patients had end-stage disease at the time of testing. We had no false negative results. The overall low remission rate in these patients reflects the poor prognosis of their advanced disease, only 13 patients being tested before first remission.
A change in drug sensitivity may be observed by testing sequentially. The ability to detect this is important in the clinical situation and offers the possibility of selecting second line agents when conventional regimes have failed. Figure 7 shows doxorubicin becoming less effective. During this time the patient relapsed and failed to gain a second remission with the original treatment. The drugs were changed and a second remission was induced using mitoxantrone, which also showed the greatest cell kill in the MTT assay. A similar pattern has since been observed in a second patient.
In conclusion, these preliminary results indicate that the MTT assay is a suitable technique for routine application to the chemosensitivity of blast cells from patients with AML. In future it may be possible to select treatment for individual patients on the basis of the rapidly acquired results of this assay. An early indication of tumour sensitivity could by implication improve early remission rates leading to a better prognosis.
